Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Request A Quote Download PDF Copy Request A Quote Download ...
Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, Inc.